+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 99Years
All Genders
ID06822010

Phase II Study of Sequential Gemcitabine and Jelmyto Treatment for Favorable High-Risk Upper Urinary Tract Urothelial Carcinoma

Led by Rutgers, The State University of New Jersey · Updated on 2026-05-06

28

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating a combination chemotherapy treatment for patients with favorable papillary high-grade upper tract urothelial carcinoma UTUC. This Phase II trial aims to assess the safety and effectiveness of sequentially administering gemcitabine and Jelmyto a gel-based form of mitomycin to potentially preserve kidney function and avoid the standard treatment of kidney removal, known as nephroureterectomy. Participants will receive six weekly doses of gemcitabine and Jelmyto directly into the affected kidney through a nephrostomy tube. Depending on the tumors response, patients may receive an additional six doses or begin a standard maintenance regimen. The study focuses on measuring the complete response rate to this treatment and its ability to manage cancer recurrence while preserving kidney health. During the study, participants will have regular follow-up evaluations lasting about three years. Researchers will monitor safety, recurrence-free survival at 12 and 24 months, and patient-reported outcomes. If the treatment is not effective, patients may still undergo the standard kidney removal procedure. The primary outcome is the complete response rate at the end of the initial treatment phase, with ongoing safety monitoring throughout the study period.

CONDITIONS

Brief Title

SeqUential GeMcitabine and MITomycin Treatment for Favorable High-Risk Upper Urinary Tract Urothelial Carcinoma

Research Team

V

Vignesh Packiam, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here